Key features and details
- Rabbit polyclonal to p27 KIP 1 (phospho T157)
- Suitable for: IHC-P, ICC/IF, WB
- Reacts with: Human
- Isotype: IgG
Product nameAnti-p27 KIP 1 (phospho T157) antibody
See all p27 KIP 1 primary antibodies
DescriptionRabbit polyclonal to p27 KIP 1 (phospho T157)
Tested applicationsSuitable for: IHC-P, ICC/IF, WBmore details
Species reactivityReacts with: Human
Predicted to work with: Cat, Dog, Pig
Synthetic peptide corresponding to Human p27 KIP 1 aa 150 to the C-terminus conjugated to keyhole limpet haemocyanin.
(Peptide available as
- This antibody gave a positive signal in the following whole cell lysates: HeLa; Jurkat; Caco2; MCF7.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help.
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab85047 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.|
|ICC/IF||Use a concentration of 5 µg/ml.|
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 32 kDa (predicted molecular weight: 22 kDa).|
FunctionImportant regulator of cell cycle progression. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichometry.
Tissue specificityExpressed in all tissues tested. Highest levels in skeletal muscle, lowest in liver and kidney.
Involvement in diseaseDefects in CDKN1B are the cause of multiple endocrine neoplasia type 4 (MEN4) [MIM:610755]. Multiple endocrine neoplasia (MEN) syndromes are inherited cancer syndromes of the thyroid. MEN4 is a MEN-like syndrome with a phenotypic overlap of both MEN1 and MEN2.
Sequence similaritiesBelongs to the CDI family.
DomainA peptide sequence containing only AA 28-79 retains substantial Kip1 cyclin A/CDK2 inhibitory activity.
modificationsPhosphorylated; phosphorylation occurs on serine, threonine and tyrosine residues. Phosphorylation on Ser-10 is the major site of phosphorylation in resting cells, takes place at the G(0)-G(1) phase and leads to protein stability. Phosphorylation on other sites is greatly enhanced by mitogens, growth factors, cMYC and in certain cancer cell lines. The phosphorylated form found in the cytoplasm is inactivate. Phosphorylation on Thr-198 is required for interaction with 14-3-3 proteins. Phosphorylation on Thr-187, by CDK2 leads to protein ubiquitination and proteasomal degradation. Tyrosine phosphorylation promotes this process. Phosphorylation by PKB/AKT1 can be suppressed by LY294002, an inhibitor of the catalytic subunit of PI3K. Phosphorylation on Tyr-88 and Tyr-89 has no effect on binding CDK2, but is required for binding CDK4. Dephosphorylated on tyrosine residues by G-CSF.
Ubiquitinated; in the cytoplasm by the KPC complex (composed of RNF123/KPC1 and UBAC1/KPC2) and, in the nucleus, by SCF(SKP2). The latter requires prior phosphorylation on Thr-187. Ubiquitinated; by a TRIM21-containing SCF(SKP2)-like complex; leads to its degradation.
Subject to degradation in the lysosome. Interaction with SNX6 promotes lysosomal degradation.
Cellular localizationNucleus. Cytoplasm. Endosome. Nuclear and cytoplasmic in quiescent cells. AKT-or RSK-mediated phosphorylation on Thr-198, binds 14-3-3, translocates to the cytoplasm and promotes cell cycle progression. Mitogen-activated UHMK1 phosphorylation on Ser-10 also results in translocation to the cytoplasm and cell cycle progression. Phosphorylation on Ser-10 facilitates nuclear export. Translocates to the nucleus on phosphorylation of Tyr-88 and Tyr-89. Colocalizes at the endosome with SNX6 and this leads to lysosomal degradation.
- Information by UniProt
- AA408329 antibody
- AI843786 antibody
- Cdki1b antibody
All lanes : Anti-p27 KIP 1 (phospho T157) antibody (ab85047) at 1 µg/ml
Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg
Lane 2 : Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate at 10 µg
Lane 3 : Caco 2 (Human colonic carcinoma cell line) Whole Cell Lysate at 10 µg
Lane 4 : MCF7 (Human breast adenocarcinoma cell line) Whole Cell Lysate at 10 µg
Lane 5 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate with Human p27 KIP 1 (phospho T157) peptide (ab97604) at 1 µg/ml
Lane 6 : Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate with Human p27 KIP 1 (phospho T157) peptide (ab97604) at 1 µg/ml
Lane 7 : Caco 2 (Human colonic carcinoma cell line) Whole Cell Lysate with Human p27 KIP 1 (phospho T157) peptide (ab97604) at 1 µg/ml
Lane 8 : MCF7 (Human breast adenocarcinoma cell line) Whole Cell Lysate with Human p27 KIP 1 (phospho T157) peptide (ab97604) at 1 µg/ml
Lane 9 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate with p27 KIP 1 peptide (ab116623) at 1 µg/ml
Lane 10 : Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate with p27 KIP 1 peptide (ab116623) at 1 µg/ml
Lane 11 : Caco 2 (Human colonic carcinoma cell line) Whole Cell Lysate with p27 KIP 1 peptide (ab116623) at 1 µg/ml
Lane 12 : MCF7 (Human breast adenocarcinoma cell line) Whole Cell Lysate with p27 KIP 1 peptide (ab116623) at 1 µg/ml
All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 22 kDa
Observed band size: 32 kDa why is the actual band size different from the predicted?
Additional bands at: 100 kDa, 75 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 2 minutes
The 32kDa band observed is comparable to the molecular weight seen with other commercially available antibodies to Human Cyclin-dependent kinase inhibitor 1B (p27 KIP 1).
IHC image of p27 KIP 1 (phospho T157) staining in human breast carcinoma formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab85047, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX
ab85047 has been referenced in 6 publications.
- Chen Y et al. Akt Regulated Phosphorylation of GSK-3ß/Cyclin D1, p21 and p27 Contributes to Cell Proliferation Through Cell Cycle Progression From G1 to S/G2M Phase in Low-Dose Arsenite Exposed HaCat Cells. Front Pharmacol 10:1176 (2019). PubMed: 31680960
- Wu C et al. SGK1 Governs the Reciprocal Development of Th17 and Regulatory T Cells. Cell Rep 22:653-665 (2018). ICC/IF ; Mouse . PubMed: 29346764
- Taniuchi K et al. WAVE2 is associated with poor prognosis in pancreatic cancers and promotes cell motility and invasiveness via binding to ACTN4. Cancer Med 7:5733-5751 (2018). PubMed: 30353690
- Li Z et al. Tumor-Secreted Exosomal miR-222 Promotes Tumor Progression via Regulating P27 Expression and Re-Localization in Pancreatic Cancer. Cell Physiol Biochem 51:610-629 (2018). PubMed: 30458449
- Rostama B et al. DLL4/Notch1 and BMP9 Interdependent Signaling Induces Human Endothelial Cell Quiescence via P27KIP1 and Thrombospondin-1. Arterioscler Thromb Vasc Biol 35:2626-37 (2015). PubMed: 26471266
- Inge LJ et al. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia. J Thorac Cardiovasc Surg 145:531-8 (2013). Human . PubMed: 23142123